…h-cost biologics such as denosumab (12%), secukinumab (8%), and epoetin beta (6%).Conclusion and Relevance The hospital pharmacy-led CMM pro…
16articles mentioning drugs
51drug mentions
1distinct drugs extracted
0%of mentions human-reviewed
Active filtersEntity: secukinumab ×
secukinumab
This drug is selected. Its supporting articles are shown below.
Articles mentioning secukinumab
16 articles · page 2 of 296.4%
epoetin betadenosumabsecukinumabrheumatoid arthritischronic kidney diseaseprostate cancerosteoporosispharmacotherapy
UstekinumabEtanerceptIxekizumabBrodalumabTildrakizumabGuselkumab=21,5 (N=23); IxekizumabRisankizumabAdalimumabGuselkumabSecukinumab
…: p=0,0482; Anti-IL12/23 vs Anti-TNF: p=0,0480; Risankizumab vs Ustekinumab: p=0,0116. No significant differences were found between Risank…
IXEixekizumabsecukinumabSECTNFiIXE-treatedpsoriatic arthritisPsA
…n for missing data. Pairwise comparisons were performed between IXE and tumour necrosis factor inhibitors (TNFi), secukinumab (SEC)…
adalimumabsecukinumab1,25(OH) 2D3Psoriatic arthritisPsA
…phenotypes were analysed by flow cytometry. Treatments included adalimumab (anti-TNFα), secukinumab (anti-IL-17A), and/or 1,25(OH) 2D3, ap…